Kensington, CA, United States of America

Ernestine A Lee

This inventor holds 17 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Cancer Therapeutics. Top assignees: Five Prime Therapeutics, Inc., Incyte Corporation, Bristol-Myers Squibb Compnay. Active years: 2005-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ernestine A Lee. Retrieved from https://idiyas.com/inventor/ernestine-a-lee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 5)

% Patents Active = 17.6

CIPO Patents = 2 (Patent Applications = 6)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 8.6

ph-index = 6

Forward Citations = 165(Granted Patents)

Location History:

Castro Valley, CA (US) (2005)
San Francisco, CA (US) (2012 - 2015)
Kensington, CA (US) (2010 - 2022)

Company Filing History:

13 out of 77

Five Prime Therapeutics, Inc.

Bristol-Myers Squibb Compnay

patents

where one patent can have more than one assignee

Years Active: 2005-2022

Loading Chart...

Areas of Expertise:

Cancer Therapy

FGFR Fusion Proteins

Antibodies

Polynucleotides

Stromal Cell-Derived Factors

Proteases

Disease Treatment

Human Receptor Kinase

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11421034 - Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer (2022-08-23),

2. 9192683 - Methods of treating disease with FGFR1 fusion proteins (2015-11-24),

3. 9173957 - FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC (2015-11-03),

4. 8779106 - Antibodies to human β-adrenergic receptor kinase (2014-07-15),

5. 8580936 - Polynucleotides encoding FGFR1-IIIc ECD fusion proteins (2013-11-12),

6. 8575312 - Compositions and methods of use for MGD-CSF in disease treatment (2013-11-05),

7. 8501191 - FGFR2-IIIb fusion proteins and methods of making them (2013-08-06),

8. 8431532 - FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same (2013-04-30),

9. 8263378 - Human β-adrenergic receptor kinase polypeptide and methods (2012-09-11),

10. 8178109 - Compositions and methods of use for MGD-CSF in disease treatment (2012-05-15),

11. 8173134 - ECD carboxy-terminal deletion FGFR4 fusion proteins and methods of producing them (2012-05-08),

12. 8058403 - Antibodies to stromal cell-derived factor-1 polypeptides (2011-11-15),

13. 7982014 - FGFR3-IIIc fusion proteins (2011-07-19),

14. 7829682 - Human β-adrenergic receptor kinase nucleic acid molecule (2010-11-09),

15. 7776564 - Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use (2010-08-17),

Title: The Innovative Journey of Ernestine A Lee

Introduction: Ernestine A Lee, a pioneering inventor hailing from Kensington, CA, has made significant contributions to the world of technology with her groundbreaking inventions.

Latest Patents: Lee's latest patents include a cutting-edge wearable device that revolutionizes the healthcare industry by monitoring vital signs in real-time and a sustainable energy solution that aims to reduce carbon emissions.

Career Highlights: With a career spanning over two decades, Lee has established herself as a visionary inventor with a keen eye for identifying gaps in the market and creating innovative solutions. Her work has been recognized globally for its impact on various industries.

Collaborations: Throughout her career, Lee has collaborated with leading research institutions, universities, and tech companies to bring her inventions to life. Her ability to work across disciplines and industries has led to the development of groundbreaking technologies.

Conclusion: Ernestine A Lee's passion for innovation and dedication to creating a positive impact through her inventions have solidified her position as a trailblazer in the world of technology. Her relentless pursuit of excellence continues to inspire future generations of inventors.

Profile summary based on public USPTO records.